Free Trial

Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis

-0.27 (-9.61%)
(As of 03:44 PM ET)
Today's Range
50-Day Range
52-Week Range
20,970 shs
Average Volume
12,885 shs
Market Capitalization
$1.52 million
P/E Ratio
Dividend Yield
Price Target
SLRX stock logo

About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

SLRX Stock Price History

SLRX Stock News Headlines

My election-year investing secret
My election-year investing secret There's only one approach I trust when things look uncertain...
SLRX Pursues Important Goal
My election-year investing secret
My election-year investing secret There's only one approach I trust when things look uncertain...
Salarius: Q4 Earnings Snapshot
Salarius Pharmaceuticals Implements Cost-savings Measures
Salarius's CEO David Arthur steps down
Salarius Pharmaceuticals Inc (SLRX)
Square Pharmaceuticals Ltd.
SLRX Continues Work as it Seeks Alternatives
Salarius Pharmaceuticals Inc SLRX
See More Headlines
Receive SLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.84 million
Book Value
$10.74 per share


Free Float
Market Cap
$1.69 million
Not Optionable

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. David J. Arthur M.B.A. (Age 61)
    CEO, President & Director
    Comp: $343.2k
  • Mr. Mark J. Rosenblum CPA (Age 71)
    Executive VP of Finance & CFO

SLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Salarius Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SLRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLRX, but not buy additional shares or sell existing shares.
View SLRX analyst ratings
or view top-rated stocks.

How have SLRX shares performed in 2024?

Salarius Pharmaceuticals' stock was trading at $5.20 at the beginning of the year. Since then, SLRX stock has decreased by 50.6% and is now trading at $2.57.
View the best growth stocks for 2024 here

Are investors shorting Salarius Pharmaceuticals?

Salarius Pharmaceuticals saw a drop in short interest during the month of May. As of May 31st, there was short interest totaling 27,300 shares, a drop of 18.5% from the May 15th total of 33,500 shares. Based on an average trading volume of 113,600 shares, the short-interest ratio is currently 0.2 days. Currently, 0.6% of the company's shares are short sold.
View Salarius Pharmaceuticals' Short Interest

When is Salarius Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our SLRX earnings forecast

How were Salarius Pharmaceuticals' earnings last quarter?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) released its earnings results on Monday, May, 13th. The company reported ($3.28) earnings per share for the quarter, beating analysts' consensus estimates of ($53.60) by $50.32.

What ETF holds Salarius Pharmaceuticals' stock?

Horizon Kinetics Medical ETF holds 31,094 shares of SLRX stock, representing 0.08% of its portfolio.

When did Salarius Pharmaceuticals' stock split?

Salarius Pharmaceuticals shares reverse split before market open on Monday, June 17th 2024. The 1-8 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX).

How do I buy shares of Salarius Pharmaceuticals?

Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLRX) was last updated on 6/21/2024 by Staff

From Our Partners